By working with industry and starting two biotechs, we have learned about clinical nanomedicine. We combine chemistry, engineering, and new manufacturing infrastructure to scale up drugs to human doses. The ability to identify nanoparticles using barcoding and then scale them up allows us to perform truly translational work in the lab.